Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exploratory double-blind, placebo-controlled study of NS-580 in chronic prostatitis/chronic pelvic pain syndrome
jRCT2031230134Phase 2Completed
- Sponsor
- Nippon Shinyaku
- Start
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of friluglanstat in Prostatodynia (CP/CPPS) (3 arms), sponsored by Nippon Shinyaku. Primary endpoint: Change in total NIH-CPSI score. Started Jun 2023; status: completed.
02
Drugs
friluglanstat
03
Conditions
Prostatodynia (CP/CPPS)
Beyond the preview
Go deeper on jRCT2031230134.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230134.